NCT06084689View on ClinicalTrials.gov

Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 14, 2024

Primary Completion Date

July 1, 2024

Study Completion Date

July 1, 2024

Conditions
Adult Soft Tissue SarcomaNon Small Cell Lung CancerTriple Negative Breast CancerColorectal CancerBiliary Tract Cancer
Interventions
DRUG

Ezabenlimab + BI907828

A treatment cycle consists of 3 weeks. Both treatments will be administered on Day 1 of each cycle.

Trial Locations (6)

33076

Institut Bergonié, Bordeaux

59000

Centre Oscar Lambret, Lille

Unknown

Centre Georges François Leclerc, Dijon

Centre Léon Bérard, Lyon

CHRU Poitiers, Poitiers

Centre Eugène Marquis, Rennes

Sponsors

Lead Sponsor

Institut Bergonié

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Institut Bergonié

OTHER

NCT06084689 - Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures | Biotech Hunter | Biotech Hunter